Potential use of glucocorticosteroids in CSF1R mutation carriers - current evidence and future directions
Neurol Neurochir Pol. 2023;57(5):444-449. doi: 10.5603/pjnns.97373. Epub 2023 Oct 27.ABSTRACTWe recently found that glucocorticosteroids (GCs) have protective effects in CSF1R mutation carriers against developing symptomatic CSF1R-related leukoencephalopathy. Our findings were subsequently confirmed in a mouse model study. We have received many questions from patients, their families, patient organisations, and healthcare practitioners about the optimal type of GCs, the dose, the route of administration, and application timing. This paper attempts to answer the most urgent of these questions based on our previous studies a...
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Jaros ław Dulski E Richard Stanley Violeta Chitu Zbigniew K Wszolek Source Type: research
To know or not to know? Opinions of patients with Parkinson's Disease on disclosing risk of phenoconversion in RBD
CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study provides important information that should influence physicians' communication with patients with RBD, especially regarding how they communicate about the high risk of phenoconversion.PMID:37888900 | DOI:10.5603/pjnns.97758 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Aneta Marcinkowska Andrzej Bogucki Aleksandra Kroemeke Agata Gajos Source Type: research
Potential use of glucocorticosteroids in CSF1R mutation carriers - current evidence and future directions
Neurol Neurochir Pol. 2023;57(5):444-449. doi: 10.5603/pjnns.97373. Epub 2023 Oct 27.ABSTRACTWe recently found that glucocorticosteroids (GCs) have protective effects in CSF1R mutation carriers against developing symptomatic CSF1R-related leukoencephalopathy. Our findings were subsequently confirmed in a mouse model study. We have received many questions from patients, their families, patient organisations, and healthcare practitioners about the optimal type of GCs, the dose, the route of administration, and application timing. This paper attempts to answer the most urgent of these questions based on our previous studies a...
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Jaros ław Dulski E Richard Stanley Violeta Chitu Zbigniew K Wszolek Source Type: research
To know or not to know? Opinions of patients with Parkinson's Disease on disclosing risk of phenoconversion in RBD
CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study provides important information that should influence physicians' communication with patients with RBD, especially regarding how they communicate about the high risk of phenoconversion.PMID:37888900 | DOI:10.5603/pjnns.97758 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Aneta Marcinkowska Andrzej Bogucki Aleksandra Kroemeke Agata Gajos Source Type: research
Potential use of glucocorticosteroids in CSF1R mutation carriers - current evidence and future directions
Neurol Neurochir Pol. 2023 Oct 27. doi: 10.5603/pjnns.97373. Online ahead of print.ABSTRACTWe recently found that glucocorticosteroids (GCs) have protective effects in CSF1R mutation carriers against developing symptomatic CSF1R-related leukoencephalopathy. Our findings were subsequently confirmed in a mouse model study. We have received many questions from patients, their families, patient organisations, and healthcare practitioners about the optimal type of GCs, the dose, the route of administration, and application timing. This paper attempts to answer the most urgent of these questions based on our previous studies and...
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Jaros ław Dulski E Richard Stanley Violeta Chitu Zbigniew K Wszolek Source Type: research
To know or not to know? Opinions of patients with Parkinson's Disease on disclosing risk of phenoconversion in RBD
CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study provides important information that should influence physicians' communication with patients with RBD, especially regarding how they communicate about the high risk of phenoconversion.PMID:37888900 | DOI:10.5603/pjnns.97758 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Aneta Marcinkowska Andrzej Bogucki Aleksandra Kroemeke Agata Gajos Source Type: research
Potential use of glucocorticosteroids in CSF1R mutation carriers - current evidence and future directions
Neurol Neurochir Pol. 2023 Oct 27. doi: 10.5603/pjnns.97373. Online ahead of print.ABSTRACTWe recently found that glucocorticosteroids (GCs) have protective effects in CSF1R mutation carriers against developing symptomatic CSF1R-related leukoencephalopathy. Our findings were subsequently confirmed in a mouse model study. We have received many questions from patients, their families, patient organisations, and healthcare practitioners about the optimal type of GCs, the dose, the route of administration, and application timing. This paper attempts to answer the most urgent of these questions based on our previous studies and...
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Jaros ław Dulski E Richard Stanley Violeta Chitu Zbigniew K Wszolek Source Type: research
To know or not to know? Opinions of patients with Parkinson's Disease on disclosing risk of phenoconversion in RBD
CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study provides important information that should influence physicians' communication with patients with RBD, especially regarding how they communicate about the high risk of phenoconversion.PMID:37888900 | DOI:10.5603/pjnns.97758 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Aneta Marcinkowska Andrzej Bogucki Aleksandra Kroemeke Agata Gajos Source Type: research
Potential use of glucocorticosteroids in CSF1R mutation carriers - current evidence and future directions
Neurol Neurochir Pol. 2023 Oct 27. doi: 10.5603/pjnns.97373. Online ahead of print.ABSTRACTWe recently found that glucocorticosteroids (GCs) have protective effects in CSF1R mutation carriers against developing symptomatic CSF1R-related leukoencephalopathy. Our findings were subsequently confirmed in a mouse model study. We have received many questions from patients, their families, patient organisations, and healthcare practitioners about the optimal type of GCs, the dose, the route of administration, and application timing. This paper attempts to answer the most urgent of these questions based on our previous studies and...
Source: Neurologia i Neurochirurgia Polska - October 27, 2023 Category: Neurology Authors: Jaros ław Dulski E Richard Stanley Violeta Chitu Zbigniew K Wszolek Source Type: research
Neurologists should retain diagnostic and therapeutic management of migraines
Neurol Neurochir Pol. 2023 Sep 14. doi: 10.5603/pjnns.96686. Online ahead of print.NO ABSTRACTPMID:37706667 | DOI:10.5603/pjnns.96686 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - September 14, 2023 Category: Neurology Authors: Josef Finsterer Source Type: research
Differences in diffusion tensor imaging parameters of brain white matter tracts between patients with myotonic dystrophy type 1 and type 2 - a retrospective single-centre study
CONCLUSIONS: Our results indicate diffuse disintegration of white matter pathways in DM patients, especially in the DM1 group. The damage to all types of fibres (association, commissural, and projection) may explain the diversity of clinical symptoms, which were more severe in the DM1 group of patients than in the DM2 group.CLINICAL IMPLICATIONS: DTI in patients with DM may help us to understand the neural mechanisms underlying brain involvement during the disease. In future, it may help to identify biomarkers for disease progression and treatment response.PMID:37706668 | DOI:10.5603/pjnns.95587 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - September 14, 2023 Category: Neurology Authors: Edyta Maj Tomasz Wolak Joanna de Meulder Katarzyna Janiszewska Miko łaj Wojtaszek Anna Kostera-Pruszczyk Marek Go łębiowski Anna Łusakowska Source Type: research
Response to 'Neurologists should retain diagnostic and therapeutic management of migraines'
Neurol Neurochir Pol. 2023 Sep 14. doi: 10.5603/pjnns.97421. Online ahead of print.NO ABSTRACTPMID:37706669 | DOI:10.5603/pjnns.97421 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - September 14, 2023 Category: Neurology Authors: Magdalena Boczarska-Jedynak Source Type: research
Neurologists should retain diagnostic and therapeutic management of migraines
Neurol Neurochir Pol. 2023 Sep 14. doi: 10.5603/pjnns.96686. Online ahead of print.NO ABSTRACTPMID:37706667 | DOI:10.5603/pjnns.96686 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - September 14, 2023 Category: Neurology Authors: Josef Finsterer Source Type: research
Differences in diffusion tensor imaging parameters of brain white matter tracts between patients with myotonic dystrophy type 1 and type 2 - a retrospective single-centre study
CONCLUSIONS: Our results indicate diffuse disintegration of white matter pathways in DM patients, especially in the DM1 group. The damage to all types of fibres (association, commissural, and projection) may explain the diversity of clinical symptoms, which were more severe in the DM1 group of patients than in the DM2 group.CLINICAL IMPLICATIONS: DTI in patients with DM may help us to understand the neural mechanisms underlying brain involvement during the disease. In future, it may help to identify biomarkers for disease progression and treatment response.PMID:37706668 | DOI:10.5603/pjnns.95587 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - September 14, 2023 Category: Neurology Authors: Edyta Maj Tomasz Wolak Joanna de Meulder Katarzyna Janiszewska Miko łaj Wojtaszek Anna Kostera-Pruszczyk Marek Go łębiowski Anna Łusakowska Source Type: research
Response to 'Neurologists should retain diagnostic and therapeutic management of migraines'
Neurol Neurochir Pol. 2023 Sep 14. doi: 10.5603/pjnns.97421. Online ahead of print.NO ABSTRACTPMID:37706669 | DOI:10.5603/pjnns.97421 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - September 14, 2023 Category: Neurology Authors: Magdalena Boczarska-Jedynak Source Type: research
